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Certain reproductive and developmental
toxicants may have the potential to interfere
with normal sexual differentiation and devel-
opment in animals and humans by modulat-
ing or interfering with the endocrine system
(McLachlan 1993; McLachlan and Korach
1995). The Organisation for Economic Co-
operation and Development (OECD) has ini-
tiated an activity to revise existing guidelines
and develop new screening and testing guide-
lines to aid in the identification and assess-
ment of such toxicants (OECD 1998, 2000,
2001, 2003).
One proposed assay, referred to as the
Hershberger assay, uses the androgen sensitivity
of several accessory sex organs and tissues of the
male reproductive tract. The assay was origi-
nally developed in the 1930s by Korenchevsky
and co-workers, and a number of accessory sex
organs and tissues were shown to be useful by
these and other investigators, including the
ventral prostate (Deanesly and Parkes 1936;
Dingemanse et al. 1935; Korenchevsky 1932;
Korenchevsky et al. 1932, 1933a, 1933b), the
seminal vesicles and coagulating glands
(Deanesly and Parkes 1936; Dingemanse et al.
1935; Korenchevsky 1932; Korenchevsky et al.
1932, 1933a, 1933b), the preputial glands
(Bülbring and Burn 1935; Korenchevsky 1932;
Korenchevsky et al. 1932, 1933a, 1933b), the
Cowper’s glands (Wainman and Shipounoff
1941), and the glans penis (Bülbring and Burn
1935; Dingemanse et al. 1935; Korenchevsky
1932; Korenchevsky et al. 1932, 1933a,
1933b). In the 1940s, it was discovered that the
levator ani and bulbocavernosus muscles also
responded to androgens, but in a different way
from the other tissues (Eisenberg and Gordan
1950; Eisenberg et al. 1949; Wainman and
Shipounoff 1941). The basis for this differen-
tial sensitivity is the presence of 5α-reductase
in most accessory tissues of the male reproduc-
tive tract but its absence in the muscle com-
plex (Di Salle et al. 1994). The capabilities of
the assay were demonstrated in 1953 by
Hershberger et al. when they analyzed the
response of the ventral prostate, seminal vesi-
cles and coagulating glands, and the levator ani
without the bulbocavernosus muscle to a num-
ber of active chemicals, including estrogens
and progesterones (Hershberger et al. 1953).
In the 1970s and 1980s, with the discovery
of the androgen receptor and the first com-
pounds such as cyprotone acetate that were
antagonists of the receptor, the assay was
modified to address antagonistic activity.
Briefly, a set dose of a reference agonist was
coadministered to several groups of animals
that were also administered a set of doses of the
purported antagonist. This modified system
was successfully used by several investigators
for assaying androgen antagonists (Peets et al.
1973; Raynaud et al. 1980, 1984; Wakeling
et al. 1981).
Therefore, based upon the recommenda-
tion of scientific workshops, both the U.S.
Endocrine Disruptor Screening and Testing
Advisory Committee (U.S. EPA 1998) and
the OECD Endocrine Disrupter Testing and
Assessment Working Group (OECD 2000)
have proposed this assay as a Tier 1 screen to
identify possible reproductive and develop-
mental toxicants acting through androgen
agonist and antagonist mechanisms.
The OECD phase 1 validation program
for the Hershberger assay was completed in
2001. In this phase, a standardized protocol
using ventral prostate, seminal vesicles with
coagulating glands, levator ani and bulbocaver-
nosus muscle complex, Cowper’s glands, and
glans penis was successfully tested against a ref-
erence androgen compound, testosterone pro-
pionate (TP), and a reference antagonist,
flutamide (OECD 2001). Therefore, the
OECD proposed a phase 2 validation program
using additional androgen agonists and antag-
onists as the next step to validate the assay.
In phase 2, the selected androgens were
methyltestosterone (MT) and trenbolone;
the selected antagonists were vinclozolin
(VCZ), procymidone, linurone, and 2,2-bis
(4-chlorophenyl)-1,1-dichloroethylene
(p,p´-DDE); and the 5α-reductase inhibitor
was ﬁnasteride. These test substances will be
used to investigate the reliability of the assay,
including a demonstration of the protocol’s
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The Organisation for Economic Co-operation and Development has initiated the development of
new guidelines for the screening and testing of potential endocrine disruptors. The Hershberger
assay is one of the assays selected for validation based on the need for in vivo screening to detect
androgen agonists or antagonists by measuring the response of ﬁve sex accessory organs and tis-
sues of castrated juvenile male rats: the ventral prostate, the seminal vesicles with coagulating
glands, the levator ani and bulbocavernosus muscle complex, the Cowper’s glands, and the glans
penis. The phase 1 feasibility demonstration stage of the Hershberger validation program has been
successfully completed with a single androgen agonist and a single antagonist as reference sub-
stances. The phase 2 validation program employs a range of additional androgen agonists and
antagonists as well as 5α-reductase inhibitors. Seven Japanese laboratories have contributed phase
2 validation studies of the Hershberger assay using methyltestosterone, vinclozolin, and 2,2-bis (4-
chlorophenyl)-1,1-dichloroethylene (p,p´-DDE). The methyltestosterone doses were 0, 0.05, 0.5,
5, and 50 mg/kg/day, and the vinclozolin and p,p´-DDE doses were 0, 3, 10, 30, and
100 mg/kg/day. All chemicals were orally administered by gavage for 10 consecutive days. In the
antagonist version of the assay using vinclozolin and p,p´-DDE, 0.2 mg/kg/day of testosterone
propionate was coadministered by subcutaneous injection. All five accessory sex preproductive
organs and tissues consistently responded with statistically signiﬁcant changes in weight within a
narrow window. Therefore, the Japanese studies support the Hershberger assay as a reliable and
reproducible screening assay for the detection of androgen agonistic and antagonistic effects. Key
words: Hershberger assay, methyltestosterone, OECD validation, p,p´-DDE, vinclozolin. Environ
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[Online 10 September 2003]transferability among laboratories and the
reproducibility of the protocol’s results. Seven
Japanese laboratories participated in the phase 2
validation study that used three of the selected
compounds: MT, VCZ, and p,p´-DDE. The
participation of the laboratories in the OECD
phase 2 validation study was performed as part
of a national validation program in Japan.
Materials and Methods
Laboratories. The seven participating Japanese
laboratories were the Chemicals Evaluation and
Research Institute (CERI); the Food Drug
Safety Center; the Institute of Environmental
Toxicology; the Japan Bioassay Research
Center; Mitsubishi Chemical Safety Institute;
Panapham Co., Ltd.; and Sumitomo Chemical
Company Ltd. Each laboratory performed in
compliance with principles of good laboratory
practice.
Test substances. The test substances were
methyltestosterone (MT; CAS No. 58-18-4;
99.8% pure; Fluka Production GmbH, St.
Louis, MO, USA), vinclozolin (VCZ; CAS
No. 50471-44-8; 99% pure; Kanto Chemical
Co., Tokyo, Japan), and p,p´-DDE (CAS No.
72-55-9; 99.5% pure; Sigma-Aldrich Co., St.
Louis, MO, USA). Testosterone propionate
(TP; CAS No. 57-85-2; 97% pure; Fluka) was
used as a reference positive chemical control
and was coadministered with VCZ and
p,p´-DDE to detect androgen antagonistic
effects. MT, p,p´-DDE, and TP were obtained
from a centralized chemical repository at
TNO (Zeist, the Netherlands) and distributed
through CERI to each laboratory; VCZ was
obtained by CERI and distributed to each lab-
oratory in the study. All laboratories used corn
oil as the vehicle. The test substances used in
each laboratory are shown in Table 1.
Animals. Laboratory details regarding rat
strain, age at castration, number of postopera-
tive acclimation days, age at autopsy, animal
diet, and the number of animals housed per
cage are summarized in Table 1. Five laborato-
ries used Crj:CD (SD) (Sprague-Dawley) cas-
trated rats from Charles River Japan, Inc.
(Kanagawa/Shiga, Japan) between the ages of
40 and 46 days, and the test substances were
administered 7–11 days after castration. Two
laboratories used Brl Han: WIST Jcl (GALAS)
castrated rats from Japan Clea, Inc. (Tokyo,
Japan) between the ages of 40 and 43 days,
and the test substances were administered 6 or
7 days after castration. In all of the laborato-
ries, the rats were weighed, weight-ranked,
and assigned to each of the experimental and
control groups after they had recovered from
castration. Body weight and clinical signs were
recorded daily throughout the study. Rats
were provided with water and a commercial
diet (MF or CRF-1, Oriental Yeast Co.,
Tokyo, Japan) ad libitum. The animals were
kept under speciﬁc-pathogen–free conditions.
The animal room was maintained at a temper-
ature of 23 ± 2°C, a relative humidity of 55 ±
15%, and artiﬁcial illumination with ﬂuores-
cent light on a 12-hr light/dark cycle. All ani-
mals were cared for according to the principles
outlined in the guide for animal experimenta-
tion prepared by the Japanese Association for
Laboratory Animal Science (1992). 
Chemical administration. Each test chemi-
cal was orally administered via a stomach tube
for 10 consecutive days at approximately the
same time each day. A vehicle control group
receiving only corn oil was used in all cases. For
the androgen antagonists (VCZ and
p,p´-DDE), 0.2 mg/kg/day of TP was co-
administered each day by subcutaneous injec-
tion in the dorsal region after the oral
administration of each chemical. In these cases,
a positive control group of animals received TP
injections alone. We selected the dose of TP on
the basis of OECD recommendations and pub-
lished data (OECD 2001; Sunami et al. 2000).
The group size in all cases was six rats. For the
TP and corn oil solutions containing each of
the test chemicals, the volume of corn oil was
5 mL/kg. The MT doses were 0.05, 0.5, 5, and
50 mg/kg/day, and the VCZ and p,p´-DDE
doses were 3, 10, 30, and 100 mg/kg/day. All
doses were selected based on the results of pre-
liminary, range-finding studies. The animals
were killed by bleeding from the abdominal
vein under deep ether anesthesia approximately
24 hr after receiving their ﬁnal dose. The ﬁve
mandatory tissues—the ventral prostate and
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Table 1. Laboratory details for test compounds and animals.
Age at Postoperative Age at No.
Laboratory Test compound(s) Rat strain castration (days) acclimation days autopsy (days) Diet per cage
1 MT, VCZ Crj:CD (SD)a 41–44 11 62–65 CRF-1 1
2 MT, VCZ, p,p´-DDE Crj:CD (SD)a 40–44 8 59–63 MF 1
3M T Crj:CD (SD)b 41–43 7 59–61 MF 3
4 MT, p,p´-DDE Crj:CD (SD)b 42–44 7 59–61 CRF-1 2
5 VCZ, p,p´-DDE Crj:CD (SD)b 43–46 7 61–64 MF 2
6 VCZ, p,p´-DDE Brl Han: WIST Jcl (GALAS) 41–43 7 59–61 MF 3
7 p,p´-DDE Brl Han: WIST Jcl (GALAS) 40–42 6 57–59 MF 3
aFacility in Kanagawa, Japan. bFacility in Shiga, Japan.
Table 2. Weights of optional organs from rats given MT, VCZ, or p,p´-DDE.
Chemical Lab Animal/tissue Dose
MT
MT (mg/kg/day) 0 0.05 0.5 5 50
1 Terminal body wt (g) 309.2 318.5 313.4 315.6 317.0
Liver (g) 12.5 13.5 13.1 12.7 13.9
Adrenals (mg) 50.5 60.4 56.1 48.1 45.3
Kidneys (g) 2.2 2.4 2.3 2.3 2.5
3 Terminal body wt (g) 282.7 288.6 293.1 290.4 288.7
Liver (g) 12.0 12.0 11.7 11.3 12.3
4 Terminal body wt (g) 287.3 286.0 281.4 293.4 294.2
Liver (g) 12.3 12.4 11.7 13.0 13.8
Adrenals (mg) 52.8 46.7 49.0 49.0 41.1*
Kidneys (g) 2.0 2.2 2.0 2.2 2.4*
VCZ
TP (mg/kg/day) 0.2 0.2 0.2 0.2 0.2
VCZ (mg/kg/day) 0 3 10 30 100
1 Terminal body wt (g) 338.4 344.7 340.3 347.4 334.0
Liver (g) 14.5 14.3 14.5 15.2 15.5
Adrenals (mg) 54.9 56.0 60.8 66.9 72.9*
Kidneys (g) 2.4 2.4 2.4 2.5 2.5
p,p´-DDE
TP (mg/kg/day) 0.2 0.2 0.2 0.2 0.2
p,p´-DDE (mg/kg/day) 0 3 10 30 100
4 Terminal body wt (g) 292.7 291.0 290.4 293.2 289.4
Liver (g) 12.8 12.4 14.3 16.5* 20.1*
Adrenals (mg) 47.2 46.8 45.7 47.6 51.2
Kidneys (g) 2.2 2.1 2.2 2.3 2.3
7 Terminal body wt (g) 240.9 241.4 241.4 238.0 235.8
Kidneys (g) 2.1 2.1 2.2 2.1 2.1
*Signiﬁcantly different from control at p < 0.05.fluid, seminal vesicle and fluid, bulbocaver-
nosus/levator ani muscle (BC/LA), glans penis,
and Cowper’s gland—were carefully dissected
free of adhering fat and weighed to the nearest
0.1 mg. Six of the laboratories weighed the
wet organs. One laboratory (Lab 4) weighed
the prostate, seminal vesicle, Cowper’s glands,
and adrenal glands after approximately 24 hr
ﬁxation in 10% formalin solution, following
the procedure of Yamada et al. (2000). The
liver, paired kidneys, and paired adrenal
glands were weighed as optional organs in
some laboratories in each assay described in
Table 2.
Statistical analysis. Body weight and organ
weight data were tested using Bartlett’s test for
homogeneity of variance. When the variances
were homogeneous at the 5% significance
level, one-way analysis of variance (ANOVA)
was performed. If it yielded signiﬁcant differ-
ences, the differences between the vehicle con-
trol group and each of the MT groups or the
positive control group and each of the VCZ
and p,p´-DDE groups were analyzed by
Dunnett’s test. When the variances were not
homogeneous, the Kruskal-Wallis test was
used. If it yielded significant differences, the
differences between each group and the corre-
sponding control group were analyzed by the
nonparametric Dunnett’s test. Log-trans-
formed organ-weight data were also tested by
the same method. The coefﬁcient of variance
(CV) and R2 values for the different effects of
each compound were also calculated by divid-
ing the sums of the squares of the ANOVA
scores for an effect by the total sum of the
squares. This calculation provides an estimate
of the strength of an effects association with an
end point. Data for each end point were also
analyzed using a two-way ANOVA, with
dosage and laboratory as the main effects, so
that the magnitude of the overall dosage and
laboratory effects could be determined. For
graphic presentation, the sex accessory organ
data were normalized to visually compare the
shapes of the dose–response curves produced
by each laboratory. For this normalization, the
control value was set to 100% in the MT assay,
and 100% in the TP without VCZ or
p,p´-DDE assays. ANOVA was performed on
the data from each laboratory and for the
pooled laboratory data; these normalized values
were not analyzed statistically.
Results
Methyltestosterone. Body weights, clinical
observations, and organ weights. The weight
changes in optional organs and the body
weights on the first day of dosing and at
necropsy are shown in Tables 2 and 3. No
significant differences in body weight were
observed between the vehicle control group
and the MT group in each laboratory. No
abnormal clinical signs were observed in any
Article | Yamasaki et al.
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Table 3. Mean body weights and mean organ weights in rats given MT: data and log-transformed data.
MT (mg/kg/day)
Lab 0 0.05 0.5 5 50
1 Starting body wt (g) 260.0 259.8 259.3 249.8 258.9
Terminal body wt (g) 309.2 318.5 313.4 315.6 317.0
Ventral prostate (mg) 21.1 20.4 18.7 40.6 135.0*
Seminal vesicles (mg) 45.2 43.7 43.3 65.7 248.2*
BC/LA (mg) 192.3 198.0 198.1 253.2* 460.5*
Glans penis (mg) 51.4 55.6 53.4 64.8* 83.2*
Cowper’s glands (mg) 6.5 7.8 7.6 10.8* 25.3*
2 Starting body wt (g) 227.5 227.3 226.9 228.0 226.7
Terminal body wt (g) 297.6 291.2 292.6 294.6 299.1
Ventral prostate (mg) 12.6 14.4 21.4 45.3 128.3*
Seminal vesicles (mg) 52.5 50.2 48.1 70.7 278.5*
BC/LA (mg) 236.3 218.9 228.7 287.3 533.8*
Glans penis (mg) 48.9 50.8 49.9 55.0* 73.3*
Cowper’s glands (mg) 6.5 6.8 7.6 11.0 27.2*
3 Starting body wt (g) 218.4 218.8 219.3 219.4 218.2
Terminal body wt (g) 282.7 288.6 293.1 290.4 288.7
Ventral prostate (mg) 19.3 22.1 26.2 51.1* 158.2*
Seminal vesicles (mg) 44.2 52.9 66.2 108.0* 312.6*
BC/LA (mg) 201.5 203.6 212.6 254.2 482.0*
Glans penis (mg) 62.6 60.8 61.9 74.4 94.7*
Cowper’s glands (mg) 8.1 7.5 9.5 11.8* 22.1*
4 Starting body wt (g) 227.4 227.4 227.8 228.5 227.3
Terminal body wt (g) 287.3 286.0 281.4 293.4 294.2
Ventral prostate (mg) 19.2 20.8 19.5 32.3* 150.9*
Seminal vesicles (mg) 39.7 37.3 34.8 41.2 184.4*
BC/LA (mg) 206.3 199.8 203.6 243.8 487.1*
Glans penis (mg) 52.8 53.1 53.7 56.8 83.5*
Cowper’s glands (mg) 6.5 7.4 5.8 7.6 26.3*
Log-transformed data
1 Ventral prostate (mg) 1.3 1.3 1.3 1.6* 2.1*
Seminal vesicles (mg) 1.7 1.6 1.6 1.8* 2.4*
BC/LA (mg) 2.3 2.3 2.3 2.4* 2.7*
Glans penis (mg) 1.7 1.7 1.7 1.8* 1.9*
Cowper’s glands (mg) 0.8 0.9 0.9 1.0 1.4*
2 Ventral prostate (mg) 1.1 1.1 1.3* 1.6* 2.1*
Seminal vesicles (mg) 1.7 1.7 1.7 1.8 2.4*
BC/LA (mg) 2.4 2.3 2.4 2.5* 2.7*
Glans penis (mg) 1.7 1.7 1.7 1.7 1.9*
Cowper’s glands (mg) 0.8 0.8 0.9 1.0* 1.4*
3 Ventral prostate (mg) 1.3 1.3 1.4 1.7* 2.2*
Seminal vesicles (mg) 1.6 1.7 1.8 2.0* 2.5*
BC/LA (mg) 2.3 2.3 2.3 2.4* 2.7*
Glans penis (mg) 1.8 1.8 1.8 1.9* 2.0*
Cowper’s glands (mg) 0.9 0.9 1.0 1.1* 1.3*
4 Ventral prostate (mg) 1.3 1.3 1.3 1.5* 2.2*
Seminal vesicles (mg) 1.6 1.6 1.5 1.6 2.3*
BC/LA (mg) 2.3 2.3 2.3 2.4 2.7*
Glans penis (mg) 1.7 1.7 1.7 1.8 1.9*
Cowper’s glands (mg) 0.8 0.9 0.8 0.9 1.4*
*Signiﬁcantly different from vehicle control at p < 0.05.
Table 4. Overall mean organ weights, R2, and CV in rats given MT: data and log-transformed data.
MT (mg/kg/day)
R2 (%) 0 0.05 0.5 5 50
Overall means TRT LAB CV (%) (n = 22–24) (n = 23–24) (n = 22–24) (n = 22–24) (n = 24)
Overall
Ventral prostate (mg) 90 1 25 18.0 19.4 21.5 42.3 143.1
Seminal vesicles (mg) 81 4 20 45.4 46.0 48.1 71.4 255.9
BC/LA (mg) 83 6 12 209.1 205.0 210.7 259.6 490.9
Glans penis (mg) 78 19 7 54.0 55.2 54.8 63.3 83.7
Cowper’s glands (mg) 81 0 22 6.9 7.4 7.6 10.3 25.2
Overall log-transformed
Ventral prostate (mg) 87 2 7.7 1.2 1.3 1.3 1.6 2.1
Seminal vesicles (mg) 83 6 4.7 1.7 1.6 1.7 1.8 2.4
BC/LA (mg) 87 2 2.2 2.3 2.3 2.3 2.4 2.7
Glans penis (mg) 77 21 1.8 1.7 1.7 1.7 1.8 1.9
Cowper’s glands (mg) 78 2 10.3 0.8 0.9 0.9 1.0 1.4
Abbreviations: TRT, R2 values for effects of treatments; LAB, R2 values for effects among laboratories. of the rats that were treated with MT. The
paired kidney weights increased significantly
at 50 mg/kg/day MT in Lab 4, and adrenal
weights decreased at the same dose in Lab 4.
Accessory sex organ weights. Accessory
sex organ weight changes and overall means
are shown in Tables 3 and 4, and normalized
organ weight changes are shown in Figure 1.
For the ventral prostate, the normalized
dose–response curves produced by the four
laboratories were similar, and the weight
change at 50 mg/kg/day MT relative to the
vehicle control ranged from 641% to 1,022%.
This was the largest weight change observed in
any of the examined organs. The R2 values for
effects of treatments (TRT) in the ventral
prostate was higher than the respective TRT
values for other organs.
The normalized dose–response curves
produced by the four laboratories were similar
for the seminal vesicle; the weight change
ranged from 465% to 707% at 50 mg/kg/day
MT relative to the vehicle control.
For BC/LA, the normalized dose–response
curves produced by the four laboratories were
almost the same, and the weight change at 50
mg/kg/day MT relative to the vehicle control
ranged from 226% to 240%.
The normalized dose–response curves 
produced by the four laboratories were similar
for the glans penis, and the weight change at
50 mg/kg/day MT relative to the vehicle con-
trol ranged from 150% to 162%. Although the
range between the low and high relative weight
changes in animals receiving 50 mg/kg/day MT
was narrow, the relative weight increase at this
dose was the smallest of the weight changes in
all of the accessory sex organs that were exam-
ined. The average CV for the glans penis was
the lowest of all the average values obtained for
the other organs. The R2 values for effects
among laboratories (LAB) for the glans penis
was the highest value obtained among the
accessory sex organs examined in this study.
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Figure 1. Weights of accessory sex organs
from rats given MT. (A) Ventral prostate.
(B) Seminal vesicle. (C) BC/LA. (D) Glans
penis. (E) Cowper’s glands. Values from
each laboratory were normalized to the
control value set equal to 100%. The toxic
dose is 50 mg/kg/day.
Table 5. Mean body weights and mean organ weights in rats given 0.2 mg/kg/day TP and VCZ: data and
log-transformed data. 
VCZ (mg/kg/day)
Lab 0 3 10 30 100
1 Starting body wt (g) 273.4 273.6 273.3 274.8 273.3
Terminal body wt (g) 338.4 344.7 340.3 347.4 334.0
Ventral prostate (mg) 136.5 118.8 91.3 60.7* 36.4*
Seminal vesicles (mg) 393.5 358.5 248.7* 174.5* 60.7*
BC/LA (mg) 533.9 511.5 441.9* 381.8* 257.8*
Glans penis (mg) 91.1 88.9 79.8* 76.8* 64.0*
Cowper’s glands (mg) 32.7 32.7 24.3* 20.2* 12.4*
2 Starting body wt (g) 241.6 241.5 240.1 241.1 241.0
Terminal body wt (g) 326.8 327.7 320.8 319.6 319.1
Ventral prostate (mg) 97.2 111.6 105.1 79.4 34.1*
Seminal vesicles (mg) 361.7 335.9 321.0 210.8* 71.8*
BC/LA (mg) 537.7 500.5 485.2 416.0* 275.2*
Glans penis (mg) 81.7 75.9 73.7 69.8 58.5*
Cowper’s glands (mg) 28.0 26.8 21.1* 20.1* 11.2*
5 Starting body wt (g) 247.6 247.6 248.3 248.0 247.7
Terminal body wt (g) 340.6 337.0 338.8 333.5 335.3
Ventral prostate (mg) 183.6 149.7* 136.7* 98.2* 51.0*
Seminal vesicles (mg) 420.8 458.7 344.3 247.7 96.4*
BC/LA (mg) 590.4 608.8 529.3 430.7* 308.6*
Glans penis (mg) 76.4 78.0 77.7 70.2 52.7*
Cowper’s glands (mg) 38.6 36.0 32.9 25.9* 16.2*
6 Starting body wt (g) 229.5 229.6 229.7 229.4 229.2
Terminal body wt (g) 291.1 289.9 286.2 286.3 289.2
Ventral prostate (mg) 106.4 98.9 84.1 75.3 38.9*
Seminal vesicles (mg) 216.7 221.6 168.4* 116.2* 47.3*
BC/LA (mg) 361.3 320.6 323.9 268.0* 181.8*
Glans penis (mg) 70.1 69.9 67.3 64.7 51.4*
Cowper’s glands (mg) 20.8 21.1 19.5 15.1 7.4*
Log-transformed data
1 Ventral prostate (mg) 2.1 2.1 1.9* 1.8* 1.5*
Seminal vesicles (mg) 2.6 2.6 2.4* 2.2* 1.8*
BC/LA (mg) 2.7 2.7 2.6 2.6* 2.4*
Glans penis (mg) 2.0 1.9 1.9* 1.9* 1.8*
Cowper’s glands (mg) 1.5 1.5 1.4* 1.3* 1.1*
2 Ventral prostate (mg) 1.9 2.0 2.0 1.9 1.5*
Seminal vesicles (mg) 2.6 2.5 2.5 2.3* 1.8*
BC/LA (mg) 2.7 2.7 2.7 2.6* 2.4*
Glans penis (mg) 1.9 1.9 1.9 1.8* 1.8*
Cowper’s glands (mg) 1.4 1.4 1.3 1.3 1.0*
5 Ventral prostate (mg) 2.3 2.2 2.1* 2.0* 1.7*
Seminal vesicles (mg) 2.6 2.7 2.5* 2.4* 2.0*
BC/LA (mg) 2.8 2.8 2.7 2.6* 2.5*
Glans penis (mg) 1.9 1.9 1.9 1.8 1.7*
Cowper’s glands (mg) 1.6 1.5 1.5 1.4* 1.2*
6 Ventral prostate (mg) 2.0 2.0 1.9 1.9 1.6*
Seminal vesicles (mg) 2.3 2.3 2.2 2.1* 1.7*
BC/LA (mg) 2.6 2.5 2.5 2.4* 2.3*
Glans penis (mg) 1.8 1.8 1.8 1.8 1.7*
Cowper’s glands (mg) 1.3 1.3 1.3 1.2* 0.9*
*Signiﬁcantly different from vehicle control at p < 0.05.For the Cowper’s glands, the normalized
dose–response curves produced by the four lab-
oratories were similar, and the weight change
ranged from 273% to 417% at 50 mg/kg/day
MT relative to the vehicle control. 
Vinclozolin. Body weights, clinical general
observations, and organ weights. The weight
changes in optional organs and the body
weight changes for VCZ-treated rats are
shown in Tables 2 and 5. No signiﬁcant dif-
ferences in body weight were observed
between the positive control group that
received TP injections alone and the VCZ
group in any of the laboratories. No abnor-
mal clinical signs were observed in any of the
rats treated with VCZ plus TP. Weight of the
paired adrenal glands increased signiﬁcantly at
100 mg/kg/day, and no other significant
changes were detected in the liver and paired
kidneys.
Accessory sex organ weights. Weight
changes in accessory sex organs and overall
means are shown in Tables 5 and 6, and
normalized organ weight changes are shown
in Figure 2.
For the ventral prostate, the normalized
dose–response curves produced by the four
laboratories were similar. The ventral prostate
weight changes at 100 mg/kg/day VCZ rela-
tive to the positive control ranged from 27%
to 37%.
The normalized dose–response curves
produced by the four laboratories were similar
for seminal vesicles. The weight changes at
100 mg/kg/day VCZ relative to the positive
control were similar, ranging from 15% to
23%. These values were the lowest of all the
values for the accessory sex organs, and the
decreasing dose–response curve for the semi-
nal vesicle was sharper than the curves for the
other organs.
For the BC/LA, the normalized dose–
response curves produced by the four laborato-
ries were similar, and the weight change at 100
mg/kg/day VCZ relative to the positive control
were similar, ranging from 48% to 52%.
The normalized dose–response curves
produced by the four laboratories were similar
for the glans penis, and the weight change at
100 mg/kg/day VCZ relative to the positive
control were similar, ranging from 69% to
73%. The overall CV value was the lowest
among the values for the examined accessory
sex organs.
The normalized dose–response curves pro-
duced by the four laboratories were similar for
Cowper’s glands. The weight change ranged
from 36% to 42% at a dose of 100 mg/kg/day
VCZ relative to the positive control. 
p,p´-DDE. Body weights, clinical obser-
vations, and organ weights. The weight
changes in optional organs and the body
weight changes for p,p´-DDE–treated rats are
shown in Tables 2 and 7. The body weight
decreased signiﬁcantly in the 100 mg/kg/day
group of Lab 5, and a similar (but not signiﬁ-
cant) tendency was also observed in the
100 mg/kg/day group of Lab 2. No abnormal
clinical signs were detected in any of the rats
treated with p,p´-DDE plus TP. The liver
weights increased significantly at 30 and
100 mg/kg/day in Lab 4. No significant
changes were observed in other organs.
Accessory sex organ weights. Weight
changes in accessory sex organs and overall
means are shown in Tables 7 and 8, and nor-
malized organ weight changes are shown in
Figure 3.
For the ventral prostate, the normalized
dose–response curves produced by the ﬁve lab-
oratories were very similar, except for the
curve produced by Lab 7 because of the value
at 30 mg/kg/day p,p´-DDE. The weight
change at a dose of 100 mg/kg/day relative to
the positive control ranged from 37% to 62%.
The normalized dose–response curves pro-
duced by the laboratories were similar at 10,
30, and 100 mg/kg/day p,p´-DDE for seminal
vesicle. The weight change of the seminal vesi-
cles at 100 mg/kg/day relative to the positive
control ranged from 23% to 54%. The dose–
response curve for the seminal vesicle was the
sharpest of the various curves produced for the
Article | Yamasaki et al.
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Figure 2. Accessory sex organ weights of
rats given VCZ plus 0.2 mg/kg/day of TP.
(A) Ventral prostate. (B) Seminal vesicle.
(C) BC/LA. (D) Glans penis. (E) Cowper’s
glands. Values from each laboratory were
normalized to the control value set equal to
100%.
Table 6. Overall mean organ weights, R2, and CV in rats given 0.2 mg/kg/day TP and VCZ: data and log-
transformed data.
VCZ (mg/kg/day)
R2 (%) 0 3 10 30 100
Overall means TRT LAB CV (%) (n = 24) (n = 24) (n = 24) (n = 24) (n = 24)
Overall
Ventral prostate (mg) 60 16 19 130.9 119.8 104.3 78.4 40.1
Seminal vesicles (mg) 64 19 19 348.2 343.7 270.6 187.3 69.1
BC/LA (mg) 50 34 12 505.8 485.3 445.1 374.1 255.9
Glans penis (mg) 67 29 7 79.8 78.2 74.7 70.4 56.7
Cowper’s glands (mg) 51 26 19 30.0 29.2 24.5 20.3 11.8
Overall log-transformed
Ventral prostate (mg) 69 11 4.8 2.1 2.1 2.0 1.9 1.6
Seminal vesicles (mg) 77 14 3.8 2.5 2.5 2.4 2.2 1.8
BC/LA (mg) 54 34 2.0 2.7 2.7 2.6 2.6 2.4
Glans penis (mg) 70 27 1.8 1.9 1.9 1.9 1.8 1.8
Cowper’s glands (mg) 59 22 6.6 1.5 1.5 1.4 1.3 1.0
Abbreviations: TRT, R2 values for effects of treatments; LAB, R2 values for effects among laboratories.accessory sex organs for p,p´-DDE. The TRT
in the seminal vesicle was the highest value
among the accessory sex organs measured in
this study.
For BC/LA, the normalized dose–response
curves produced by four laboratories were sim-
ilar. The weight change ranged from 55% to
72% at 100 mg/kg/day p,p´-DDE relative to
the positive control.
The normalized dose–response curves
were similar in glans penis above a dose of
30 mg/kg/day p,p´-DDE. The weight change
at 100 mg/kg/day p,p´-DDE relative to the
positive control ranged from 79% to 86%,
and this percentage was the highest among the
values for the accessory sex organs receiving
p,p´-DDE. The CV of the glans penis and the
BC/LA were smaller than the values for the
other organs. The TRT for the glans penis was
the smallest of the values observed among the
accessory sex organs in p,p´-DDE–treated rats.
For Cowper’s glands, the normalized
dose–response curves produced by the labora-
tories were similar above a dose of 30
mg/kg/day p,p´-DDE. The weight change at
100 mg/kg/day relative to the positive control
ranged from 41% to 65%.
Discussion
Seven Japanese laboratories performed the
Hershberger assay using MT, VCZ, and
p,p´-DDE as part of a national validation pro-
gram. The weights of all the accessory sex
organs from the experimental animals in all
the laboratories exhibited significant dose-
related changes in the assays using agonistic
MT or antagonistic VCZ and p,p´-DDE; the
normalized dose–response curves showed that
all ﬁve tissues reacted in a similar manner for
each compound. Furthermore, the weights of
all the tissues treated with middle and/or high
doses in each assay fell within narrow ranges.
Therefore, we consider the Hershberger assay,
as proposed by the OECD, to be a good
screening assay for detecting the androgen
agonistic and antagonistic effects of chemicals.
The OECD proposed TP doses of 0.2
mg/kg/day and 0.4 mg/kg/day to detect antag-
onistic effects of chemicals based on the data
from the OECD phase 1 validation of the
Hershberger assay (OECD 2001). In the previ-
ous study, we used the 0.2 mg/kg/day dose of
TP in Hershberger assays of 30 chemicals
based on the OECD draft protocol and found
that the accessory sex organ weights of the cas-
trated rats were lower than those of castrated
rats given TP, and the weights of these organs
in rats given 10 mg/kg/day ﬂutamide plus TP
were also lower than in castrated rats given TP
(Yamasaki et al. 2003). In addition, the
weights of the accessory sex organs of the cas-
trated rats were lower than those of castrated
rats given 0.4 mg/kg/day TP, and their weights
were also lower in noncastrated rats than in
castrated rats given TP (Yamasaki et al. 2002).
We selected the 0.2 mg/kg/day dose in this
study, however, a dose of 0.4 mg/kg/day was
used in the phase 2 validation studies except in
Japan (OECD 2003). The sensitivity of this
assay of antagonistic chemicals at the
0.2 mg/kg/day and 0.4 mg/kg/day doses needs
to be compared.
The OECD phase 1 validation of the
Hershberger assay using antagonistic ﬂutamide
reported that the seminal vesicle exhibited the
most sensitive end point and that the glans
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Table 7. Mean body weights and mean organ weights in rats given 0.2 mg/kg/day TP and p,p´-DDE: data
and log-transformed data.
p,p´-DDE (mg/kg/day)
Lab 0 3 10 30 100
2 Starting body wt (g) 229.7 228.9 230.4 230.7 228.4
Terminal body wt (g) 313.4 313.4 313.0 317.3 303.3
Ventral prostate (mg) 137.8 125.7 128.9 93.6* 51.5*
Seminal vesicles (mg) 387.2 272.3* 377.0 256.0* 88.3*
BC/LA (mg) 549.9 521.9 519.4 458.5* 300.4*
Glans penis (mg) 73.3 76.5 73.5 73.6 63.0*
Cowper’s glands (mg) 27.2 21.8 28.3 23.7 17.4*
4 Starting body wt (g) 224.6 223.8 223.6 222.5 224.0
Terminal body wt (g) 292.7 291.0 290.4 293.2 289.4
Ventral prostate (mg) 115.0 101.3 103.3 74.7* 48.7*
Seminal vesicles (mg) 237.2 219.5 251.4 156.8* 82.7*
BC/LA (mg) 495.5 496.6 450.9 395.1* 301.5*
Glans penis (mg) 81.0 80.1 77.6 76.2 66.7*
Cowper’s glands (mg) 30.2 28.1 25.5 24.2 12.3*
5 Starting body wt (g) 233.2 232.6 231.8 233.0 232.8
Terminal body wt (g) 319.4 326.9 322.9 323.6 307.3*
Ventral prostate (mg) 153.3 158.4 165.9 141.8 77.6*
Seminal vesicles (mg) 371.1 432.6 411.8 326.1 148.1*
BC/LA (mg) 518.7 574.3 547.0 490.9 291.3*
Glans penis (mg) 77.3 75.9 76.5 74.0 60.8*
Cowper’s glands (mg) 33.9 33.8 32.8 32.6 20.2*
6 Starting body wt (g) 217.1 217.1 216.2 217.0 218.2
Terminal body wt (g) 276.6 270.2 272.6 274.7 273.0
Ventral prostate (mg) 106.2 89.8 100.0 71.7* 52.5*
Seminal vesicles (mg) 225.7 219.4 202.4 164.5 75.1*
BC/LA (mg) 300.3 305.7 290.3 309.0 209.9*
Glans penis (mg) 67.0 62.3 66.3 65.0 56.6*
Cowper’s glands (mg) 21.0 21.5 19.8 15.4* 11.0*
7 Starting body wt (g) 173.8 173.7 174.0 174.2 173.8
Terminal body wt (g) 240.9 241.4 241.4 238.0 235.8
Ventral prostate (mg) 90.6 79.1 88.1 89.6 56.5*
Seminal vesicles (mg) 282.8 246.2 240.0 231.6 152.0*
BC/LA (mg) 435.7 430.3 407.0 408.2 311.9*
Glans penis (mg) 65.5 64.9 63.8 66.9 52.0*
Cowper’s glands (mg) 26.2 26.7 25.4 25.9 17.0*
Log-transformed
2 Ventral prostate (mg) 2.1 2.1 2.1 2.0 1.7*
Seminal vesicles (mg) 2.6 2.4 2.6 2.4 1.9*
BC/LA (mg) 2.7 2.7 2.7 2.7* 2.5*
Glans penis (mg) 1.9 1.9 1.9 1.9 1.8*
Cowper’s glands (mg) 1.4 1.3 1.4 1.4 1.2*
4 Ventral prostate (mg) 2.1 2.0 2.0 1.9* 1.7*
Seminal vesicles (mg) 2.4 2.3 2.4 2.2* 1.9*
BC/LA (mg) 2.7 2.7 2.7 2.6* 2.5*
Glans penis (mg) 1.9 1.9 1.9 1.9 1.8*
Cowper’s glands (mg) 1.5 1.4 1.4 1.4 1.1*
5 Ventral prostate (mg) 2.2 2.2 2.2 2.1 1.9*
Seminal vesicles (mg) 2.6 2.6 2.6 2.5 2.2*
BC/LA (mg) 2.7 2.8 2.7 2.7 2.5*
Glans penis (mg) 1.9 1.9 1.9 1.9 1.8*
Cowper’s glands (mg) 1.5 1.5 1.5 1.5 1.3*
6 Ventral prostate (mg) 2.0 2.0 2.0 1.8* 1.7*
Seminal vesicles (mg) 2.3 2.3 2.3 2.2* 1.9*
BC/LA (mg) 2.5 2.5 2.5 2.5 2.3*
Glans penis (mg) 1.8 1.8 1.8 1.8 1.7*
Cowper’s glands (mg) 1.3 1.3 1.3 1.2* 1.0*
7 Ventral prostate (mg) 2.0 1.9 1.9 1.9 1.7*
Seminal vesicles (mg) 2.4 2.4 2.4 2.4 2.2*
BC/LA (mg) 2.6 2.6 2.6 2.6 2.5*
Glans penis (mg) 1.8 1.8 1.8 1.8 1.7*
Cowper’s glands (mg) 1.4 1.4 1.4 1.4* 0.2*
*Signiﬁcantly different from vehicle control at p < 0.05.penis exhibited the least sensitive end point,
based on benchmark dose estimates (OECD
2001). When the overall dose–response
curves for agonistic TP were compared, the
glans penis was the most sensitive and the
seminal vesicle was the least sensitive (OECD
2001). In the present study, it was difﬁcult to
select a particularly sensitive organ from
among the ﬁve tissues examined in the andro-
gen agonistic MT and antagonistic VCZ and
p,p´-DDE assays. In the Hershberger assay
using MT, the CV for the glans penis was
smaller than that of the other organs, but the
TRT of the ventral prostate was the highest
among the values measured in the study. On
the other hand, the LAB values of the ventral
prostate and Cowper’s glands were smaller
than the values of the other organs, and the
percentage weight change relative to the con-
trol value at the highest dose was the greatest
in the ventral prostate. These findings
demonstrate that the ventral prostate was par-
ticularly sensitive based on the TRT, LAB,
and increasing percentage of organ weight,
whereas the glans penis was sensitive based on
the CV values. Similarly, the seminal vesicle
was sensitive based on the TRT, LAB, and
decreasing percentage of organ weight,
whereas the glans penis was sensitive based on
the CV values in the assays using antagonistic
VCZ and p,p´-DDE.
The CV values for the ventral prostate,
seminal vesicle, and Cowper’s gland were
higher than those for the glans penis and
BC/LA in the assays for all three chemicals.
These organs contain ﬂuid, and the dissection
of these organs is technically difficult, com-
pared with that of the glans penis and
BC/LA. These technical issues may have
inﬂuenced the varied CV values obtained for
these organs. Furthermore, we did not con-
firm whether preputial separation had
occurred in the rats before castration.
Preputial separation has been reported to
occur between days 39 and 44 in SD rats
(Yamasaki et al. 2001); in this study, the cas-
tration was performed between days 40 and
46. Thus, the rats used in this study were
likely a mixture of animals with or without
preputial separation. The castration times
may also have inﬂuenced the variation in the
CV values for each organ.
In the assay using the androgen antagonistic
chemicals, slight differences in the normalized
response curves for low doses in the p,p´-DDE
assay were observed among the laboratories,
but the response curves for each organ in the
VCZ assay were similar. The fact that the per-
centages of organ weight relative to the control
at high doses in the p,p´-DDE assay were lower
than those in the VCZ assay suggests that the
androgen antagonistic afﬁnity of p,p´-DDE is
weaker than that of VCZ. On the other hand,
the organ weights of the rats given only TP
varied among the laboratories. The slight varia-
tion in responses among the laboratories for
the low dose in the p,p´-DDE assay may have
been affected by the relationship between the
agonistic afﬁnity of TP and the weak antago-
nistic afﬁnity of p,p´-DDE.
In the phase 1 validation study using TP,
the OECD reported that no essential differ-
ences were observed when the weights of the
fresh and fixed organs were compared
(OECD 2001). Lab 4 weighed the prostate,
seminal vesicle, and Cowper’s glands after ﬁx-
ation, whereas the other laboratories mea-
sured the weights of fresh organs; the changes
in organ weight among the laboratories were
essentially similar. Therefore, the difference in
the weighing method (fresh vs. ﬁxed organs)
did not appear to affect the results of the
assay. Although the terminal body weights
were different between SD and Wistar rats,
the responsiveness of these rats to VCZ and
p,p´-DDE did not differ in this study. This
finding demonstrates that no significant dif-
ferences exist regarding the use of SD and
Wistar rats in the Hershberger assay for the
detection of androgen antagonists.
Among the optional organs measured in
this study, the weight of the adrenal glands
increased significantly in rats given 100
mg/kg/day of VCZ and decreased in rats given
50 mg/kg/day MT. The decrease in adrenal
weight may be suppressed by a high dose of
Article | Yamasaki et al.
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Table 8. Overall mean organ weights, R2, and CV in rats given 0.2 mg/kg/day TP and p,p´-DDE: data and
log-transformed data.
p,p´-DDE (mg/kg/day)
R2 (%) 0 3 10 30 100
Overall means TRT LAB CV (%) (n = 30) (n = 30) (n = 30) (n = 30) (n = 30)
Overall
Ventral prostate (mg) 36 32 20 120.6 110.9 117.2 94.3 57.3
Seminal vesicles (mg) 45 31 19 300.8 278.0 296.5 227.0 109.2
BC/LA (mg) 37 42 10 460.0 465.8 442.9 412.3 283.0
Glans penis (mg) 30 37 7 72.8 71.9 71.5 71.1 59.8
Cowper’s glands (mg) 33 29 19 27.7 26.4 26.4 24.4 15.6
Log-transformed
Ventral prostate (mg) 48 23 4.4 2.1 2.0 2.1 2.0 1.7
Seminal vesicles (mg) 59 20 3.7 2.5 2.4 2.5 2.3 2.0
BC/LA (mg) 40 43 1.7 2.7 2.7 2.6 2.6 2.4
Glans penis (mg) 31 35 1.8 1.9 1.9 1.9 1.9 1.8
Cowper’s glands (mg) 40 25 6.3 1.4 1.4 1.4 1.4 1.2
Abbreviations: TRT, R2 values for effects of treatments; LAB, R2 values for effects among laboratories. 
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Figure 3. Weights of accessory sex organs
from rats given p,p´-DDE plus 0.2 mg/kg/day
of TP. (A) Ventral prostate. (B) Seminal vesi-
cle. (C) BC/LA. (D) Glans penis. (E) Cowper’s
glands. Values from each laboratory were
normalized to the control value set equal to
100%. Toxic doses are 30 and 100 mg/kg/day.Article | Hershberger assay validation in Japan
Environmental Health Perspectives • VOLUME 111 | NUMBER 16 | December 2003 1919
androgen in the form of MT, and the adrenal
glands may be hypertrophied in response to a
high level of antagonist. Increased kidney
weights in rats given 50 mg/kg/day of MT
and increased liver weights in rats given 30
and 100 mg/kg/day of p,p´-DDE suggested
toxic effects. On the other hand, a signiﬁcant
decrease or a tendency to decrease of the body
weights in the p,p´-DDE assay was observed
by two out of ﬁve laboratories; this response
was also considered to be a toxic effect of
p,p´-DDE.
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